The Role Of Tumor Marker CA 15-3 in Detection of Breast Cancer Relapse After Curative Mastectomy

유방암 환자에서 근치적 유방 절제술 후 재발 발견에 대한 CA 15-3의 역할

  • Hyun, In-Young (Department of Nuclear Medicine, Inha University College of Medicine) ;
  • Kim, In-Ho (Department of Internal Medicine, Inha University College of Medicine) ;
  • Lee, Moon-Hee (Department of Internal Medicine, Inha University College of Medicine) ;
  • Kim, Chul-Soo (Department of Internal Medicine, Inha University College of Medicine)
  • 현인영 (인하대학교 병원, 핵의학과) ;
  • 김인호 (인하대학교 병원, 혈액종양 내과) ;
  • 이문희 (인하대학교 병원, 혈액종양 내과) ;
  • 김철수 (인하대학교 병원, 혈액종양 내과)
  • Published : 2004.08.31

Abstract

Purpose: The purpose of this study was to determine the utility of tumor marker CA 15-3 in the following: the diagnosis of breast cancer relapse after curative mastectomy, and the differentiation or the value of tumor marker by site of metastases. Materials and Methods: Two hundred two patients (median age 48 years) with breast cancer included in the follow-up after curative mastectomy. The tumor marker CA 15-3 was determined by IRMA (CIS BIO INTERNATIONAL, France). Test values > 30 U/ml were considered elevated (positive). Results: Among 202 patients, recurrent diseases were found in 16 patients. CA 15-3 was elevated in 5 of 16 patients with recurrences. There was no false-positive patient who had elevated CA 15-3. Sensitivity and specificity of CA 15-3 for detection of breast cancer recurrence were 31%, and 100%. CA 15-3 was elevated in all of the 4 patients with liver metastases. CA 15-3 was elevated in none of the patients who relapsed with metastasis to bone-only or contralateral breast-only. Conclusion: The tumor marker CA 15-3 in the detection of breast cancer relapse after curative mastectomy is specific, but not sensitive. However, it is useful to rule out liver metastases of breast cancer, which indicates bad prognosis.

References

  1. Ministry of Health and Welfare, Republic of Korea Annual Report of Cancer Registry Programme in the Republic of Korea. (2000.1.1-2000.12.31), 2002
  2. Fisher B, Slack N, Katrych D, Wolmark N: Ten years follow-up results of patients with carcinoma of the breast in a cooperative trial evaluation surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34
  3. O'Rourke TJ: Tumor markers. In; Calabresi P, Schein PS, et al. Medical oncology: basic principles and clinical management of cancer, 2nd ed., pp 163-172, New York, Mcgraw-Hill, inc., 1993
  4. Hayes DF, Zurawski NR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clinic Oncol 1986;4:1542-50 https://doi.org/10.1200/JCO.1986.4.10.1542
  5. ASCO Special Article. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77 https://doi.org/10.1200/JCO.1996.14.10.2843
  6. ASCO Special Article. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:2149-56
  7. ASCO Special Article. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78
  8. Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, et al. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Res 1986;46:5444-50
  9. Thompson CH, Jones SL, Whitehead RH, McKenzie IF. A human breast tissue-associated antigen detected by a monoclonal antibody. J Natl Cancer Inst 1983;70:409-19
  10. Moon SD, Jung SS, Kim IC, Lee DS. Comparison of CA 15-3 with CEA as tumor marker of breast cander. J of Korean Cancer Assoc 1992;24:829-33
  11. Kim H, Le YH. CA 15-3 in patients with primary and recurrent breast cancer. J Korean Surg Soc 1995;50:36-41
  12. Jung JH, Park HY, Lee YH. Clinical value of CEA, CA 15-3 and TPS in breast cancer. J Korean Breast Cancer Soc 2001;4:136-43 https://doi.org/10.4048/jkbcs.2001.4.2.136
  13. Cheung KL. Editorial comment on 'Serum markers in breast cancer management' Eur J Cancer 2002;38:1165-6
  14. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002;38:1181-8
  15. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 2002;38:1189-93 https://doi.org/10.1016/S0959-8049(01)00429-4
  16. Krengli M, Pastore G, Maffei S. The importance of the follow-up in patients operated on for breast cancer. A retrospective analysis of 2482 cases. Minerva Med 1993;84:409-15
  17. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-214
  18. Kim HK, Heo DS, BangY-J, Kim NK. Pattern of recurrence of breast cancer in Korean female patients. J of Korean Cancer Assoc 1999;31:509-16
  19. Kim S-H. Chemotherapy of breast cancer. Kor J Med 2000;58:497-509
  20. Wojtacki J, Kruszewski WJ, Sliwinska M, Kruszewska E, Hajdukiewicz W, Sliwinski W, et al. Elevation of serum CA 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 2001;58:498-503
  21. Buffaz P-D, Gauchez A-S, Caravel J-P, Vuillez J-P, Cura C, Agnius-Delord C, et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999;26:8-11